Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The partners inked a licensing deal to market and distribute TGen's DeepChek-TB as a compact, portable, and affordable diagnostic model for physician use.
Omega said that the technical file supporting its CE mark will form the basis for seeking additional regulatory approvals.
The deal will enable the Australian firm to distribute its diagnostic tests in the United Arab Emirates, Saudi Arabia, Bahrain, Qatar, and Oman.
Hardy Dx will distribute EliTechGroup's Mycofast US for detecting, enumerating, and identifying genital Mycoplasma hominis and Ureaplasma urealyticum.
The Australian maker of multiplexed molecular diagnostics tests has now partnered with distributors in Germany, Austria, Sweden, and Turkey.
The test can detect resistance to two of the most commonly prescribed antibiotics used to treat strep throat, and could potentially be adapted for point-of-care use.
Along with WHO, Mologic, and Leiden University Medical Center, FIND is developing two rapid diagnostic tests to detect circulating anodic antigen in blood or urine.
Regional Medical Laboratory, a commercial reference lab, is using the Alinity next-gen immunoassay system in the face of growing test volumes and a shortage of trained labor.
The test will leverage next-generation sequencing to sequence PCR amplicons of the UL54 and UL97 genes in which drug resistance with CMV has been associated.
Sona said it manufactures gold nanorods that could be integrated into the multiplexed lateral flow assays that Olm Diagnostics is developing.
Revenues included sales to the former US lab business and revenue from T-SPOT.TB tests sold to Quest after Nov. 6 as part of a long-term supply agreement.
The companies will standardize and automate Qiagen's QuantiFeron-TB Gold Plus test workflow on Tecan's Fluent laboratory automation workstation.
The firm said it secured a record 14 new contracts of T2Dx instruments in the fourth quarter, which was at the high end of its guidance for the second half of 2018.
The researchers said that their proof-of-concept microfluidic platform is 1,000 times more sensitive than a traditional ELISA.
The test is designed to identify and differentiate between Zika, dengue, and chikungunya in serum samples, even in the presence of more than one target.
BioMérieux received clearance for its Vitek 2 gram-negative susceptibility card as a test used to determine the antimicrobial susceptibility of certain aerobic bacilli.
In an SEC document, the company said net proceeds are expected to be $5.8 million and will be used to support an anticipated submission to the FDA, among other things.
Since moving to rapid molecular testing, the lab has doubled its billable test volume, largely through increasing clients for its outreach lab services.
The firm's technology mimics infection in an in vitro setting in order to detect an immune response indicative of a latent infection.